{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T00:04:38Z","timestamp":1759017878538,"version":"3.44.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.clinthera.2020.04.006","type":"journal-article","created":{"date-parts":[[2020,6,6]],"date-time":"2020-06-06T07:22:29Z","timestamp":1591428149000},"page":"1067-1076.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Population Pharmacokinetics Analysis of Quetiapine Extended-release Formulation in Japanese Patients with Bipolar Depression"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2801-7528","authenticated-orcid":false,"given":"Risa","family":"Fukushi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masataka","family":"Katashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanji","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akitsugu","family":"Takada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2\u20133","key":"10.1016\/j.clinthera.2020.04.006_bib1","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/BF02244923","article-title":"Seroquel: biochemical profile of a potential atypical antipsychotic","volume":"112","author":"Saller","year":"1993","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.clinthera.2020.04.006_bib2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s002130050492","article-title":"Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia","volume":"135","author":"Gefvert","year":"1998","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.clinthera.2020.04.006_bib3","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1517\/14656566.8.9.1211","article-title":"A\u00a0preclinical and clinical rationale for quetiapine in mood syndromes","volume":"8","author":"McIntyre","year":"2007","journal-title":"Expert Opin Pharmacother"},{"issue":"Suppl 5","key":"10.1016\/j.clinthera.2020.04.006_bib4","first-page":"40","article-title":"Atypical antipsychotics in bipolar depression: potential mechanisms of action","volume":"66","author":"Yatham","year":"2005","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2020.04.006_bib5","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0006-8993(02)03570-9","article-title":"Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism","volume":"956","author":"Ichikawa","year":"2002","journal-title":"Brain Res"},{"issue":"Suppl 8","key":"10.1016\/j.clinthera.2020.04.006_bib6","first-page":"30","article-title":"Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety","volume":"66","author":"Blier","year":"2005","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2020.04.006_bib7","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejphar.2004.09.053","article-title":"The atypical antipsychotic quetiapine increases both noradrenaline and dopamine release in the rat prefrontal cortex","volume":"504","author":"Pira","year":"2004","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.clinthera.2020.04.006_bib9","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2147\/NDT.S39303","article-title":"Dosing frequency and adherence in chronic psychiatric disease: systematic review and meta-analysis","volume":"9","author":"Medic","year":"2013","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.clinthera.2020.04.006_bib10","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1007\/s12325-010-0067-9","article-title":"The role of quetiapine extended release in the treatment of bipolar depression","volume":"27","author":"Cristancho","year":"2010","journal-title":"Adv Ther"},{"key":"10.1016\/j.clinthera.2020.04.006_bib11","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/2045125312453935","article-title":"Use of quetiapine XR and quetiapine IR in clinical practice for hospitalized patients with schizophrenia: a retrospective study","volume":"2","author":"Eriksson","year":"2012","journal-title":"Ther Adv Psychopharmacol"},{"key":"10.1016\/j.clinthera.2020.04.006_bib12","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1007\/s00213-018-4977-6","article-title":"Multi-center, randomized, double-blind, placebo-controlled study of quetiapine extended-release formulation in Japanese patients with bipolar depression","volume":"235","author":"Murasaki","year":"2018","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.clinthera.2020.04.006_bib13","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s12888-019-2181-9","article-title":"Long-term mood\/antidepressant effects of quetiapine extended-release formulation: an open-label, non-controlled extension study in Japanese patients with bipolar depression","volume":"19","author":"Kanba","year":"2019","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.clinthera.2020.04.006_bib14","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s40262-013-0127-9","article-title":"Pharmacokinetics and tolerability of extended-release quetiapine fumarate in Han Chinese patients with schizophrenia","volume":"53","author":"Li","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2020.04.006_bib15","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1067\/mcp.2000.110975","article-title":"Prediction of the outcome of a phase 3 clinical trial of an antischizophrenic agent (quetiapine fumarate) by simulation with a population pharmacokinetic and pharmacodynamic model","volume":"68","author":"Kimko","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2020.04.006_bib16","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/jcph.544","article-title":"Population pharmacokinetic modeling of quetiapine after administration of Seroquel and Seroquel XR formulations to Western and Chinese patients with schizophrenia, schizoaffective disorder, or bipolar disorder","volume":"55","author":"Zhou","year":"2015","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2020.04.006_bib17","unstructured":"Pharmaceutical affairs bureau\/safety division notification no.80, June 29, 1992.s"},{"key":"10.1016\/j.clinthera.2020.04.006_bib18","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s10928-007-9060-6","article-title":"Derivation of various NONMEM estimation methods","volume":"34","author":"Wang","year":"2007","journal-title":"J\u00a0Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.clinthera.2020.04.006_bib19","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1185\/03007995.2013.794774","article-title":"Pharmacokinetic profile of the extended-release formulation of quetiapine fumarate (quetiapine XR): clinical implications","volume":"29","author":"Bui","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2020.04.006_bib20","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","article-title":"Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models","volume":"13","author":"Bergstrand","year":"2011","journal-title":"AAPS J"},{"key":"10.1016\/j.clinthera.2020.04.006_bib21","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A\u00a0new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br J Psychiatry"},{"issue":"271","key":"10.1016\/j.clinthera.2020.04.006_bib22","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1600-0447.1978.tb02357.x","article-title":"A\u00a0comprehensive psychopathological rating scale","author":"Asberg","year":"1978","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"10.1016\/j.clinthera.2020.04.006_bib23","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1176\/appi.ajp.162.7.1351","article-title":"A\u00a0randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression","volume":"162","author":"Calabrese","year":"2005","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clinthera.2020.04.006_bib24","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1097\/01.jcp.0000248603.76231.b7","article-title":"Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study)","volume":"26","author":"Thase","year":"2006","journal-title":"J\u00a0Clin Psychopharmacol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291820301922?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291820301922?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:53:18Z","timestamp":1758963198000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291820301922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S0149291820301922"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2020.04.006","relation":{},"ISSN":["0149-2918"],"issn-type":[{"type":"print","value":"0149-2918"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Population Pharmacokinetics Analysis of Quetiapine Extended-release Formulation in Japanese Patients with Bipolar Depression","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2020.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}